Pro- and anti-inflammatory factors cooperate to control hyaluronan synthesis in lung fibroblasts.
Hyaluronan (HA) is an important constituent of the extracellular matrix and accumulates during inflammatory lung diseases like asthma. Little is known about the factors that regulate HA synthesis by lung cells. Accordingly, we investigated the effect of T-helper 1 (TH1) and 2 (TH2) cytokines and the anti-inflammatory agents fluticasone and salmeterol on HA synthesis in human lung fibroblasts. Interleukin-1beta (IL-1beta) and tumor necrosis factor (TNF)-alpha were the most potent stimulators of HA synthesis and when combined, caused synergistic increases in HA accumulation. Time-course analysis of HA accumulation and [3H]-glucosamine incorporation into HA demonstrated continued synthesis over the 24 h of stimulation. Peak synthesis at 6-12 h coincided with an increased proportion of high molecular weight HA. Reverse transcriptase polymerase chain reaction (RT-PCR) revealed that IL-1beta and TNF-alpha induced HA synthase-2 messenger RNA (mRNA) 3 h following stimulation and remained elevated throughout the 24-h stimulation period. Fluticasone inhibited IL-1beta and TNF-alpha induced HA synthesis (44.5%) whereas salmeterol had no effect. When combined, fluticasone and salmeterol inhibited HA synthesis to a greater extent (85.2%). Further, fluticasone attenuated IL-1beta and TNF-alpha stimulated hyaluronan synthase-2 messenger RNA (mRNA), and the addition of salmeterol cooperatively enhanced this inhibition. These results indicate that enhanced synthesis of HA by the proinflammatory cytokines IL-1beta and TNF-alpha can be abrogated by specific corticosteroid and beta2 blocker combinations shown to be effective in the treatment of asthma.
Wilkinson
Thomas S
TS
Department of Vascular Biology, The Hope Heart Institute, Seattle, WA 98104-2046, USA.
Potter-Perigo
Susan
S
Tsoi
Christina
C
Altman
Leonard C
LC
Wight
Thomas N
TN
D000420:Albuterol / Q000031:analogs & derivatives* / Q000494:pharmacology; D000730:Androstadienes / Q000494:pharmacology; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001249:Asthma / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D001980:Bronchi / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D002478:Cells, Cultured; D016207:Cytokines / Q000276:immunology / Q000494:pharmacology; D004347:Drug Interactions / Q000502:physiology; D005347:Fibroblasts / Q000276:immunology / Q000378:metabolism*; D000068298:Fluticasone; D005944:Glucosamine / Q000494:pharmacology; D014453:Glucuronosyltransferase; D006801:Humans; D000076002:Hyaluronan Synthases; D006820:Hyaluronic Acid / Q000096:biosynthesis*; D018836:Inflammation Mediators / Q000276:immunology / Q000378:metabolism*; D007375:Interleukin-1 / Q000276:immunology / Q000494:pharmacology; D008168:Lung / Q000276:immunology / Q000378:metabolism; D011014:Pneumonia / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D000068299:Salmeterol Xinafoate; D018417:Th1 Cells / Q000276:immunology / Q000378:metabolism; D018418:Th2 Cells / Q000276:immunology / Q000378:metabolism; D014166:Transferases / Q000235:genetics; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000494:pharmacology
D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D018836:Inflammation Mediators; D007375:Interleukin-1; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D000068299:Salmeterol Xinafoate; D006820:Hyaluronic Acid; D000068298:Fluticasone; D014166:Transferases; D014453:Glucuronosyltransferase; D000076002:Hyaluronan Synthases; D005944:Glucosamine; D000420:Albuterol